Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.
about
Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.Antihypertensive effects of lofexidine in patients with essential hypertensionLabetalol disposition and concentration-effect relationships during pregnancy.Guanfacine: effects of long-term treatment and withdrawal.Differences in psychic performance with guanfacine and clonidine in normotensive subjectsClonidine increases bone resorption in humans.Pharmacological properties of the central antihypertensive agent, moxonidine.Discrepant antihypertensive dose recommendations.Evaluating the transition from dexmedetomidine to clonidine for agitation management in the intensive care unit.Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study.Severe poisoning in a child caused by a small dose of clonidine.Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose.Clonidine disposition in children; a population analysis.A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.The Fourth Lilly Prize Lecture, University of Aberdeen, September 1980. The clinical pharmacology of clonidine and related central antihypertensive agents.Central α2-adrenoceptors and blood pressure regulation in man: Studies with guanfacine (BS 100-141) and azepexole (BHT 933).Effects of clonidine infusion and withdrawal on blood pressure and behaviour in the rat. A preliminary study.Alpha-2-adrenoceptor function in alcohol withdrawal: a pilot study of the effects of iv. clonidine in alcoholics and normals.Hypertensive Patients and Their Management in Dentistry
P2860
Q34449736-56964512-67A3-4482-AD91-B36A3F8BC921Q34450146-FD27C414-6195-4EE4-B58D-EDAD51E5974CQ34512371-B57AC44B-8A0F-417D-9B34-19C8AC1C009DQ34519237-68BB1578-D266-43DD-9ED9-0151D39085DAQ34519274-858890E4-CC17-4B63-BF77-7B631862799CQ36620566-FCA53133-604B-4D8D-A41E-6B7C5C14B803Q37925014-76C574F3-AD3F-4066-AD5C-AC33719937CCQ39749051-B21D9EC4-1930-4440-9CF6-13BFDE4E96FDQ39878530-FEBC69E4-6585-4625-B88A-C5EA0C77A94FQ40484029-3A4EC0F1-88D7-40D1-BAD0-97D3F10DCE85Q41159975-019265A9-043C-48A1-913E-25130B6FAD9DQ41731588-A2EA8C1F-B3CB-433F-A165-68DB241DC497Q42078232-AB0AE0E9-CF27-4EFF-B6CB-1662125BCCDAQ42630510-0F5C50FB-DBF6-4C86-AE62-03FDA400A233Q43224246-601AC2E0-B2B2-4D50-98C4-B879CB742C5FQ43241171-489F2B60-9C54-46FD-9DEB-25EBEEA9C61BQ46135623-16481E1D-2DDC-4DFE-9C3A-2F3F73115805Q49156555-B2A4F7C7-70BE-46BC-B140-7BB0590E2E33Q52488171-89E22D8D-2CEE-450F-92A9-B4D25046A35DQ58995566-4CA19C10-52C6-45FA-B75A-4F898630D669
P2860
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh-hant
name
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@en
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@nl
type
label
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@en
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@nl
prefLabel
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@en
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@nl
P2093
P356
P1476
Pharmacokinetic and concentrat ...... ine in essential hypertension.
@en
P2093
P2888
P304
P356
10.1007/BF00561067
P577
1977-12-01T00:00:00Z